B cells as a therapeutic target in autoimmune disease

Jörg J. Goronzy, Cornelia M. Weyand

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid arthritis have opened the discussion about whether mechanisms beyond the removal of potentially pathogenic antibodies are effective in B-cell depletion. B cells may modulate T-cell activity through capturing and presenting antigens or may participate in the neogenesis of lymphoid microstructures that amplify and deviate immune responses. Studies exploring which mechanisms are functional in which subset of patients hold the promise of providing new and rational treatment approaches for autoimmune syndromes.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalArthritis Research and Therapy
Volume5
Issue number3
StatePublished - 2003

Keywords

  • Autoantibody
  • Autoimmunity
  • B-cell depletion
  • Rheumatoid arthritis
  • Systemic lupus erythematosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'B cells as a therapeutic target in autoimmune disease'. Together they form a unique fingerprint.

Cite this